Halozyme Q3 royalty revenue up 15% to $114.4M; raises 2023 EBITDA & EPS guidance

HALOZYME THERAPEUTICS, INC.

2023-Q3 EPS reported $1.45 revenue$599,214,000

GAAP diluted EPS $0.61, non-GAAP $0.75; royalty revenue $114.4M (+15% YoY).
Total revenue $216M (+3% YoY); operating income $88.3M vs $83.3M.
Accelerates remaining $250M share repurchase into 2023 via ASR (immediate).
Raises 2023 EBITDA guidance to $430-445M, non-GAAP EPS to $2.70-2.80.
Partner milestones: positive CheckMate-67T, Phesgo Japan approval, Tecentriq SC US launch delay to 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HALOZYME THERAPEUTICS, INC. reported third quarter ended September 30, 2023 results: revenue $216.0 million, EPS $0.61. Guidance raised.

Period: third quarter ended September 30, 2023
Revenue: $216.0 million
EPS: $0.61
Guidance: raised
Result: reported results

Exact text from the filing

endpoints in patients with relapsing forms of multiple sclerosis (“MS”) or primary progressive MS (“RMS” or “PPMS”). Third Quarter 2023 Financial Highlights: • Revenue was $216.0 million compared to $209.0 million in the third quarter of 2022. The 3% year-over-year increase was driven by growth in ENHANZE ® revenue streams with an increase in royalty revenue and

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-23-000056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.